Trials / Completed
CompletedNCT02505776
Safety and Patient Satisfaction With GLASH VISTA™ (Bimatoprost 0.03%) in the Treatment of Eyelash Hypotrichosis in Japan
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,699 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a post-marketing surveillance study in Japan that will evaluate the safety and patient satisfaction with GLASH VISTA™ (bimatoprost cutaneous solution 0.03%) in the treatment of hypotrichosis of the eyelashes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bimatoprost cutaneous solution 0.03% | Bimatoprost cutaneous solution 0.03% (GLASH VISTA™) prescribed as per standard of care in clinical practice. |
Timeline
- Start date
- 2014-12-08
- Primary completion
- 2018-05-21
- Completion
- 2018-05-21
- First posted
- 2015-07-22
- Last updated
- 2018-08-14
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02505776. Inclusion in this directory is not an endorsement.